Company profile: Artara Therapeutics
1.1 - Company Overview
Company description
- Provider of investigational cell and intravenous therapies, including TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations based on immunopotentiator OK-432, and IV Choline Chloride to address choline deficiency in patients on parenteral nutrition, aiming to be the first FDA-approved IV choline formulation.
Products and services
- IV Choline Chloride: Architects an investigational-stage intravenous therapy addressing choline deficiency in patients on parenteral nutrition, potentially becoming the first FDA-approved IV choline formulation
- TARA-002: Engineers an investigational-stage cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, based on the immunopotentiator OK-432 to address these indications
- Therapeutic Development Programs: Develops investigational-stage medicare products for diseases therapeutics, focusing on non-muscle invasive bladder cancer, lymphatic malformations, and choline deficiency in parenteral nutrition patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Artara Therapeutics
Liminal Biosciences
HQ: Canada
Website
- Description: Provider of state-of-the-art bio-separation technologies and therapeutic programs, including LMNL6511, a selective GPR84 antagonist for inflammatory and fibrotic diseases expected to enter Phase 1 clinical trials; an OXER1 antagonist in preclinical for eosinophilic-driven diseases (asthma, atopic dermatitis); and a discovery-stage liver-safe GPR40 agonist for type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liminal Biosciences company profile →
Inozyme Pharma
HQ: United States
Website
- Description: Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inozyme Pharma company profile →
CymaBay
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development and commercialization of proprietary new medicines for important human diseases, including Seladelpar—an investigational treatment for primary biliary cholangitis—and PBC-focused clinical trials such as IDEAL, AFFIRM, PBC with Hepatic Impairment, ASSURE, and RESPONSE.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CymaBay company profile →
Calliditas Therapeutics
HQ: Sweden
Website
- Description: Provider of specialty pharmaceuticals for unmet medical needs in niche indications, including TARPEYO (delayed-release budesonide for renal diseases), Kinpeygo (renal and hepatic diseases), NEFECON (candidate for primary IgA nephropathy), and Setanaxib (NOX1/4 inhibitor in trials for PBC and head & neck cancer), plus pipeline development for orphan renal/hepatic diseases and strategic partnerships for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calliditas Therapeutics company profile →
OrsoBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrsoBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Artara Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Artara Therapeutics
2.2 - Growth funds investing in similar companies to Artara Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Artara Therapeutics
4.2 - Public trading comparable groups for Artara Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →